» Articles » PMID: 28259087

Medical Marijuana Policies and Hospitalizations Related to Marijuana and Opioid Pain Reliever

Overview
Publisher Elsevier
Specialty Psychiatry
Date 2017 Mar 5
PMID 28259087
Citations 72
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Twenty-eight states in the U.S have legalized medical marijuana, yet its impacts on severe health consequences such as hospitalizations remain unknown. Meanwhile, the prevalence of opioid pain reliever (OPR) use and outcomes has increased dramatically. Recent studies suggested unintended impacts of legalizing medical marijuana on OPR, but the evidence is still limited. This study examined the associations between state medical marijuana policies and hospitalizations related to marijuana and OPR.

Methods: State-level annual administrative records of hospital discharges during 1997-2014 were obtained from the State Inpatient Databases (SID). The outcome variables were rates of hospitalizations involving marijuana dependence or abuse, opioid dependence or abuse, and OPR overdose in 1000 discharges. Linear time-series regressions were used to assess the associations of implementing medical marijuana policies to hospitalizations, controlling for other marijuana- and OPR-related policies, socioeconomic factors, and state and year fixed effects.

Results: Hospitalizations related to marijuana and OPR increased sharply by 300% on average in all states. Medical marijuana legalization was associated with 23% (p=0.008) and 13% (p=0.025) reductions in hospitalizations related to opioid dependence or abuse and OPR overdose, respectively; lagged effects were observed after policy implementation. The operation of medical marijuana dispensaries had no independent impacts on OPR-related hospitalizations. Medical marijuana polices had no associations with marijuana-related hospitalizations.

Conclusion: Medical marijuana policies were significantly associated with reduced OPR-related hospitalizations but had no associations with marijuana-related hospitalizations. Given the epidemic of problematic use of OPR, future investigation is needed to explore the causal pathways of these findings.

Citing Articles

The relationship of medical and recreational cannabis laws with opioid misuse and opioid use disorder in the USA: Does it depend on prior history of cannabis use?.

Martins S, Bruzelius E, Mauro C, Santaella-Tenorio J, Boustead A, Wheeler-Martin K Int J Drug Policy. 2025; 136:104687.

PMID: 39793270 PMC: 11821435. DOI: 10.1016/j.drugpo.2024.104687.


Measuring the Impact of Medical Cannabis Law Adoption on Employer-Sponsored Health Insurance Costs: A Difference-in-Difference Analysis, 2003-2022.

Doucette M, Hemraj D, Fisher E, Macfarlan D Appl Health Econ Health Policy. 2024; 23(1):119-129.

PMID: 39287774 DOI: 10.1007/s40258-024-00913-0.


Concurrent substance use among cancer patients with and without a history of cannabis use since cancer diagnosis at an NCI-Designated Cancer Center in Florida.

Islam J, Nguyen O, Turner K, Martinez Y, Rodriguez O, Rodriguez D J Natl Cancer Inst Monogr. 2024; 2024(66):224-233.

PMID: 39108241 PMC: 11303859. DOI: 10.1093/jncimonographs/lgad036.


Impact of Δ-Tetrahydrocannabinol and oxycodone co-administration on measures of antinociception, dependence, circadian activity, and reward in mice.

Slivicki R, Wang J, Nhat V, Kravitz A, Creed M, Gereau 4th R bioRxiv. 2023; .

PMID: 38105953 PMC: 10723318. DOI: 10.1101/2023.12.04.569809.


The impact of recreational cannabis laws on cannabis use disorder during "treat and release" visits to hospital emergency departments in four U.S. states, 2017-2020.

Kurtzman E, Barnow B Prev Med Rep. 2023; 36:102492.

PMID: 38021411 PMC: 10652101. DOI: 10.1016/j.pmedr.2023.102492.


References
1.
Hall W, Lynskey M . Is cannabis a gateway drug? Testing hypotheses about the relationship between cannabis use and the use of other illicit drugs. Drug Alcohol Rev. 2005; 24(1):39-48. DOI: 10.1080/09595230500126698. View

2.
Wen H, Hockenberry J, Cummings J . The effect of medical marijuana laws on adolescent and adult use of marijuana, alcohol, and other substances. J Health Econ. 2015; 42:64-80. DOI: 10.1016/j.jhealeco.2015.03.007. View

3.
Reisfield G, Wasan A, Jamison R . The prevalence and significance of cannabis use in patients prescribed chronic opioid therapy: a review of the extant literature. Pain Med. 2009; 10(8):1434-41. DOI: 10.1111/j.1526-4637.2009.00726.x. View

4.
Kolodny A, Courtwright D, Hwang C, Kreiner P, Eadie J, Clark T . The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health. 2015; 36:559-74. DOI: 10.1146/annurev-publhealth-031914-122957. View

5.
. Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008. MMWR Morb Mortal Wkly Rep. 2011; 60(43):1487-92. View